Omni Peptides
PT-141
Couldn't load pickup availability
PT-141 (also known as Bremelanotide or PT141) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). This research compound has attracted substantial scientific interest for its selective agonism at melanocortin receptors (primarily MC3R and MC4R), predominantly expressed in the central nervous system. Preliminary and advanced preclinical studies indicate that PT-141 may activate hypothalamic pathways to enhance sexual arousal and desire, induce penile erections in animal models, and modulate sexual behavior without direct reliance on vascular mechanisms. Researchers utilize this peptide in laboratory and animal models to investigate mechanisms of central sexual response, libido regulation, hypoactive sexual desire disorder (HSDD), and erectile dysfunction. As a research-grade compound, PT-141 is intended exclusively for in vitro and animal studies (note: bremelanotide has received regulatory approval for specific clinical indications such as HSDD in premenopausal women under the brand Vyleesi, but research formulations remain designated for laboratory use). Scientists value its unique CNS-targeted action, distinguishing it from PDE5 inhibitors, and its utility in elucidating melanocortin-mediated pathways in reproductive neuroendocrinology.
Research Applications
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.
— About this compound
PT-141 is a synthetic melanocortin receptor agonist peptide.
PT-141 (also known as Bremelanotide or PT141) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). This research compound has attracted substantial scientific interest for its selective agonism at melanocortin receptors (primarily MC3R and MC4R), predominantly expressed in the central nervous system. Preliminary and advanced preclinical studies indicate that PT-141 may activate hypothalamic pathways to enhance sexual arousal and desire, induce penile erections in animal models, and modulate sexual behavior without direct reliance on vascular mechanisms. Researchers utilize this peptide in laboratory and animal models to investigate mechanisms of central sexual response, libido regulation, hypoactive sexual desire disorder (HSDD), and erectile dysfunction. As a research-grade compound, PT-141 is intended exclusively for in vitro and animal studies (note: bremelanotide has received regulatory approval for specific clinical indications such as HSDD in premenopausal women under the brand Vyleesi, but research formulations remain designated for laboratory use). Scientists value its unique CNS-targeted action, distinguishing it from PDE5 inhibitors, and its utility in elucidating melanocortin-mediated pathways in reproductive neuroendocrinology.
Research Applications
Where researchers apply it.
— Verified & Documented
Every vial is backed by a Certificate of Analysis.
Each lot is independently characterised by HPLC and mass spectrometry, with identity, mass and purity documented per batch and available on request.
Additional quality-control testing, including sterility, endotoxin and heavy metals, is conducted periodically across our product range.
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.